MedTrace Logo

Effect of TPN171H on Spermatogenesis

NCT05585931 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2023-02-21

No results posted yet for this study

Summary

This study is a phaseⅠstudy to determine the acute effects of TPN171H on semen function in healthy male subjects.

Conditions

Interventions

DRUG

TPN171H 10mg

Subjects were given 10mg TPN171H tablet with 240 mL warm water under fasting condition.

DRUG

TPN171H Placebo

Subjects were given Placebo with 240 mL warm water under fasting condition.

Sponsors & Collaborators

  • Vigonvita Life Sciences

    lead INDUSTRY

Principal Investigators

  • Hui Jiang · Peking University First Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-11-15
Primary Completion
2022-12-16
Completion
2022-12-16

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05585931 on ClinicalTrials.gov